Bravecto 500 mg chewable tablets for medium-sized dogs (>10 - 20 kg)

Χώρα: Μαλαισία

Γλώσσα: Αγγλικά

Πηγή: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Δραστική ουσία:

FLURALANER

Διαθέσιμο από:

Intervet (m) Sdn Bhd

INN (Διεθνής Όνομα):

FLURALANER

Μονάδες σε πακέτο:

1 Tablets

Κατασκευάζεται από:

Intervet GesmbH

Φύλλο οδηγιών χρήσης

Not applicable

Αρχείο Π.Χ.Π.

PSC020A15 01 R2 608x304mm Black x:15mm y:35mm 906
PACKAGE LEAFLET FOR: BRAVECTO™ CHEWABLE TABLETS FOR DOGS
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bravecto 112.5 mg chewable tablets for very small dogs (2 – 4.5kg)
Bravecto 250 mg chewable tablets for small dogs (>4.5 – 10 kg)
Bravecto 500 mg chewable tablets for medium-sized dogs (>10 – 20 kg)
Bravecto 1000 mg chewable tablets for large dogs (>20 – 40 kg)
Bravecto 1400 mg chewable tablets for very large dogs (>40 – 56 kg)
STATEMENT OF THE ACTIVE SUBSTANCE
Each chewable tablet contains:
BRAVECTO CHEWABLE TABLETS
FLURALANER (MG)
for very small dogs (2 – 4.5 kg)
112.5
for small dogs (>4.5 – 10 kg)
250
for medium-sized dogs (>10 – 20 kg)
500
for large dogs (>20 – 40 kg)
1000
for very large dogs (>40 – 56 kg)
1400
PHARMACEUTICAL FORM
Chewable tablet.
Light to dark brown tablet with smooth or slightly rough surface and
circular shape. Some marbling, speckles
or both may be visible.
TARGET SPECIES
Dogs
INDICATIONS
For the treatment of tick and flea infestations in dogs.
This veterinary medicinal product is a systemic insecticide and
acaricide that provides:
-
immediate and persistent flea (_Ctenocephalides felis_) killing
activity for 12 weeks,
-
immediate and persistent tick killing activity for 12 weeks for
_Ixodes ricinus_,_ Dermacentor reticulatus_ and
_D. variabilis_,
-
immediate and persistent tick killing activity for 8 weeks for
_Rhipicephalus sanguineus_.
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the active
substance. The onset of effect is within 8 hours of attachment for
fleas (_C. felis_) and 12 hours of attachment
for ticks (_I. ricinus_).
The product can be used as part of a treatment strategy for the
control of flea allergy dermatitis (FAD).
For the treatment of demodicosis caused by_ Demodex canis_.
For the treatment of sarcoptic mange (_Sarcoptes scabiei _var.
_canis_) infestation.
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance or to
any of the excipie